Translate page

Perspectives on the scientific aspects of the meeting from Professor Daniela Krause
Georg-Speyer Haus
University of Frankfurt (Germany) 

  • Concept of treatment-free remission
    • Immunological surveillance after treatment discontinuation
    • Analysis of different immune subsets 
    • A mathematical model for prediction of good response
  • Results from the workshop on metabolism 
  • The role of inflammation in CML
  • Aging - mutations that occur with aging
  • Therapy resistance
  • Stem cells and microenvironment
  • Existence of BCR-ABL independent mutations
  • Immunotherapy - resistance to CAR-T cells

 We apologize for the background noise in this video.

Highlights from the John Goldman Conference on CML 2019:
CML experts give their personal perspectives

Perspectives on the clinical aspects of the meeting from Professor Jorge Cortes
Georgia Cancer Center
Augusta University, Augusta (USA)

  • Treatment-free remission as a new goal for patients with CML
    • Long-term follow-up data from the STIM study
    • Treatment strategies for patients with early and late relapse 
    • Biomarkers to predict a higher probability of relapse
    • Pharmacoeconomics of treatment discontinuation
  • Complex genetics of CML - the work of the Genomics Alliance
  • Clinical trial updates
    • SPIRIT trial
    • BEYOND study
    • Asciminib combinations
  • Fatigue during TKI therapy


Highlights from the John Goldman Conference on CML 2018:
CML experts give their personal perspectives

In Spanish:
Perspectivas sobre los estudios de discontinuación de terapia que se mostraron
Dr Carolina Pavlovsky
FUNDALEU - Fundación para combatir la leucemia
Buenos Aires - Argentina

  • Resumen de los estudios de discontinuacíon de terapia más importantes, que incluyen
    • ENESTFreedom
    • ENESTStop
    • DASFree
  • Análisis de los estudios actuales sobre biomarcadores y otros factores predictivos que pueden predecir el éxito terapéutico y que pueden mostrar qué mutaciones pueden ser relevantes en pacientes resistentes

Highlights from ASH 2018 Annual Meeting:

At ASH in San Diego, the CML education session was entitled 'With Great Success Comes Great Responsibility'. Professors Jane Apperley, Timothy Hughes and Charles Craddock gave respective presentations on the treatment of CML with TKIs, molecular monitoring to aid clinical decision making and the role of transplantation in managing CML. Below are interviews from the presenters on their perspectives on the session. 

These summaries are brought to you with support from Bristol Myers Squibb.

In addition, we are pleased to be able to offer you a complete scientific summary of the education session on CML. This also contains a summary of relevant abstracts on; TFR failure, resistance and new drug development.

Download the scientific summary report here

Summaries of the ASH CML Education Session

The Argument for Using Imatinib in CML

Professor Jane Apperley
Imperial College London, London, UK

Jane Apperley described the outcome of newly diagnosed patients newly treated with first or second generation TKIs. She discussed balancing the desire to achieve the deep molecular responses that permit trials of TKI discontinuation with the potential adverse effects of earlier use of the more potent TKI's, and provided pragmatic advice regarding treatment decisions.  

Importance of Molecular Monitoring in CML: How Deep, How Often, and How Should it Influence Therapy?

Professor Timothy Hughes
Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, Australia

Tim Hughes explored the appropriate time-dependent molecular targets for CML patients on TKI and the reasons why those targets differ, especially when considering treatment discontination. He also discussed the facts that influence the choice of TKI when molecular responses are not optimal and highlighted the critical role of molecular monitoring in managaging treatment-free remission.   

We Do Still Transplant CML, Don't We?

Professor Charles Craddock
Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK

Charles Craddock summarised the results of alloSCT in all phases of CML and discussed factors affecting decision-making now that increased donor availability and reduced intensity conditioning regimes have increased the number of transplant eligible patients. As disease relapse remains a major cause of treatment failure he focused on emerging peri- and post-transplant strategies to improve the outcome.